Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The vaccines are currently only authorised for emergency use in the country
Subscribe To Our Newsletter & Stay Updated